ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

REVBW Revelation Biosciences Inc

0.0127
-0.00045 (-3.42%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 300
Bid Price 0.01
Ask Price 0.0298
News -
Company Name Stock Ticker Symbol Market Type
Revelation Biosciences Inc REVBW NASDAQ Equity Warrant
  Price Change Change Percent Stock Price Last Traded
-0.00045 -3.42% 0.0127 19:50:01
Open Price Low Price High Price Close Price Prev Close
0.0127 0.0127 0.0127 0.0127 0.01315
Trades Volume VWAP Dollar Volume Avg Volume
2 300  0.0126999  4 -
Last Trade Time Type Quantity Stock Price Currency
16:00:00 300  0.0127 USD

Revelation Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
62.97k 6.30M - 0 -120k -0.02 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Revelation Biosciences

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No REVBW Message Board. Create One! See More Posts on REVBW Message Board See More Message Board Posts

REVBW Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.